Last updated on November 2019

A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment


Brief description of study

This study will evaluate the safety, tolerability, and potential effects on cognition of GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with Parkinson's disease and cognitive impairment.

Detailed Study Description

This is a randomized, double-blind, placebo-controlled study to assess the safety and tolerability of GRF6021, a plasma derived product, administered by intravenous (IV) infusion to subjects with Parkinson's disease (PD) and cognitive impairment. The study duration for the subjects will be approximately 7 months.

Clinical Study Identifier: NCT03713957

Find a site near you

Start Over

Research Centers of America, LLC

Hollywood, FL United States
2.38miles
  Connect »

MD Clinical

Hallandale Beach, FL United States
9.55miles
  Connect »